NB500-704

antibody from Novus Biologicals

Targeting: ERCC1 RAD10

Western blot (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Supportive data in Antibodypedia)

Antibody Data

Product number

NB500-704

Provider

Novus Biologicals

Proper citation

Novus Cat#NB500-704, RRID:AB_789776

Product name

Mouse Monoclonal ERCC1 Antibody

Antibody type

Monoclonal

Description

Protein G purified.

Reactivity

Human, Rat

Host

Mouse

Isotype

IgG

Vial size

0.1 ml

Concentration

1.0 mg/ml

Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

References

Submitted references

A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).

Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR
Cancer 2014 Aug 1;120(15):2343-51

---

Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.

Ozcan MF, Dizdar O, Dincer N, Balcı S, Guler G, Gok B, Pektas G, Seker MM, Aksoy S, Arslan C, Yalcin S, Balbay MD
Urologic oncology 2013 Nov;31(8):1709-15

---

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jul 1;31(19):2404-12

---

Gemcitabine causes telomere attrition by stabilizing TRF2.

Su CH, Chu WC, Lan KH, Li CP, Chao Y, Lin HC, Lee SD, Tsai YC, Lee WP
European journal of cancer (Oxford, England : 1990) 2012 Dec;48(18):3465-74

---

Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.

Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T
European journal of cancer (Oxford, England : 1990) 2012 Dec;48(18):3378-85

---

Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10.

Soltermann A, Kilgus-Hawelski S, Behnke S, Storz M, Moch H, Bode B
Journal of clinical bioinformatics 2011 Sep 30;1:25

---

ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.

Besse B, Massard C, Haddad V, Andre F, Dunant A, Pirker R, Olaussen KA, Brambilla E, Fouret P, Soria JC
Annals of oncology : official journal of the European Society for Medical Oncology 2011 Mar;22(3):575-581

---

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.

Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH
British journal of cancer 2010 Sep 7;103(6):845-51

---

Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.

Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL
Japanese journal of clinical oncology 2010 Apr;40(4):286-93

---

Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ
Cancer research 2009 Sep 1;69(17):6831-8

---

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.

Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K
Cancer 2008 Sep 15;113(6):1379-86

---

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.

Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K
British journal of cancer 2008 Jul 8;99(1):167-72

---

Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.

Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jul 1;14(13):4225-31

---

The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells.

Al-Minawi AZ, Saleh-Gohari N, Helleday T
Nucleic acids research 2008 Jan;36(1):1-9

---

ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication.

Azim HA Jr, Pruneri G, Raviele PR, Steffanoni S, Martinelli G, Peccatori FA
Journal of the Egyptian National Cancer Institute 2007 Sep;19(3):176-7

Immunohistochemistry

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Analysis of ERCC1 in human non-small cell lung cancer. Image courtesy of product review submitted by Alex Soltermann.

Supportive validation

Submitted by

Novus Biologicals (provider)

Main image

Experimental details

Immunohistochemistry-Paraffin: ERCC1 Antibody (8F1) [NB500-704] - Formalin fixed paraffin embedded human tonsil stained with ERCC1 antibody.